August 2021: Ozempic Associated With Heightened Risk of Diabetic Retinopathy Study results focused on diabetic retinopathy (DR) in patients taking semaglutide found that a higher risk for DR complications were observed with semaglutide in patients with proliferative and non-proliferative DR at baseline. However, researchers do acknowledge that worsening DR can be from rapid drops in blood glucose levels from diabetic medications
Peptides focus on cellular signaling and tissue repair, while typical drugs commonly block general inflammatory cascades
The SUSTAIN-6 study demonstrated a 26% reduction in major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke in high-risk patients with type 2 diabetes
The onset of action is fast, and the observed weight loss varies between 15% to 20% of total body weight for the newer agents, such as semaglutide
Glucagon-like peptide-1 (GLP-1) receptor agonists are injectable medications used primarily for type 2 diabetes management and, in some formulations, for chronic weight management